Investigational drug · Phase 2
Evexomostat
Also called: SDX-7320
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for HR+/HER2-negative Breast Cancer, Metastatic Breast Cancer.
Phase 2Last checked: Nov 20, 2026Latest source record: Apr 22, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "Evexomostat"
First trial start
2022
Aug 26, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Evexomostat", any sponsor or status.
Conditions studied
As listed on its trial records.
- HR+/HER2-negative Breast Cancer
- Metastatic Breast Cancer
Approved drugs for the same conditions: Breast cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "Evexomostat" as an intervention, largest first.
Memorial Sloan Kettering Cancer CenterAcademic, hospital or other
NCT05570253 · 55 participants (planned) · Start Oct 3, 2022 · Primary completion Oct 2027
Drug: Eribulin; SDX-7320 · For: Breast Cancer; Metastatic Triple-Negative Breast Cancer
Sites: Miami, Florida; Atlanta, Georgia; Basking Ridge, New Jersey · 10 sites in all
SynDevRx, Inc.Industry
NCT05455619 · 52 participants (planned) · Start Aug 26, 2022 · Primary completion Dec 2026
Drug: Evexomostat · For: HR+/HER2-negative Breast Cancer; Metastatic Breast Cancer
Sites: Loma Linda, California; Newport, California; San Diego, California · 10 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Evexomostat (SDX-7320), a methionine aminopeptidase type 2 inhibitor, stimulates weight loss and inhibits obesity-accelerated tumor growth.
Cornelius P, Mayes BA, Dannenberg AJ, et al. · Front Oncol 2026
- A Phase 1 Safety Study of Evexomostat (SDX-7320) in Patients with Late-Stage Cancer: An Antiangiogenic, Insulin-Sensitizing Drug Conjugate Targeting METAP2.
Mita MM, Mita AC, Carver BJ, et al. · Cancer Res Commun 2025
- Pharmacological Characterization of SDX-7320/Evexomostat: A Novel Methionine Aminopeptidase Type 2 Inhibitor with Anti-tumor and Anti-metastatic Activity.
Cornelius P, Mayes BA, Petersen JS, et al. · Mol Cancer Ther 2024
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.